SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors

Patient reported quality of life measured using the validated quality of life questionnaire C30 (QLQ-C30), developed by the European Organisation for Research and Treatment of Cancer. This scale includes 5 functional and 3 symptom scales, each scored as a 0-100 scale, where higher scores indicate a better outcome on functional scales and global health status, and a worse outcome on symptoms.

Patient-reported quality of life, measured using the EORTC QLQ-SURV100 a validated quality-of-life questionnaire developed by the European Organization for Research and Treatment of Cancer, evaluates survivorship-specific domains for QOL among disease-free survivors at least 1 year post-treatment, along with the validated EORTC disease-specific modules for the appropriate cancer type, and when applicable, 3 provisional site-specific survivorship modules. The SURV100 comprises 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. Essentials survivorship scales consist of 73 items to evaluate short and long-term physical, psychological, and social domains unique to disease-free cancer survivors. Scores range from 0 to 100. A high score on a functional scale indicates a high/healthy level of functioning; a high score on the global health status/QL indicates a high QL, and a high score on a symptom item indicates a high level of symptomatology.

Patient (anal carcinoma only) reported quality of life measured using questionnaire QLQ-ANL27, a validated 27-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with anal carcinoma. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (cholangiocarcinoma and gallbladder cancer only) reported quality of life measured using questionnaire QLQ-BIL21, a validated 21-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with cholangiocarcinoma and gallbladder cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (brain tumor only) reported quality of life measured using questionnaire QLQ-BN20, a validated 20-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with brain tumors. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (breast cancer only) reported quality of life measured using questionnaire QLQ-BR42, a validated 42-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with breast cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (chronic lymphocytic leukemia only) reported quality of life measured using questionnaire QLQ-CLL17, a validated 17-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with chronic lymphocytic leukemia. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (colorectal cancer only) reported quality of life measured using questionnaire QLQ-CR29, a validated 29-item health-related quality of life questionnaire developed by the European Organization for Research and Treatment of Cancer for patients with colorectal cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (cervical cancer only) reported quality of life measured using questionnaire QLQ-CX24, a validated 24-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with cervical cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms

Patient (endometrial cancer only) reported quality of life measured using questionnaire QLQ-EN24, a validated 24-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with endometrial cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (neuroendocrine carcinoind only) reported quality of life measured using questionnaire QLQ-GINET21, a validated 21-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with neuroendocrine carcinoid. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (hepatocellular carcinoma only) reported quality of life measured using questionnaire QLQ-HCC18, a validated 18-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with hepatocellular carcinoma. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (Hodgkin Lymphoma only) reported quality of life measured using questionnaire QLQ-HL27, a validated 27-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with Hodgkin Lymphoma. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (head & neck cancer only) reported quality of life measured using questionnaire QLQ-HN43, a validated 43-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with head & neck cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (lung cancer only) reported quality of life measured using the questionnaire QLQ-LC29, a validated 29-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with lung cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (colorectal liver metastasis only) reported quality of life measured using questionnaire QLQ-LMC21, a validated 21-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with colorectal liver metastasis. It is used in conjunction with the core EORTC QLQ-C30 questionnaire to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (multiple myeloma only) reported quality of life measured using questionnaire QLQ-MY20, a validated 20-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with multiple myeloma. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (high-grade non-Hodgkin lymphoma cancer only) reported quality of life measured using the questionnaire QLQ-NHL-HG29, a validated 29-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with high-grade non-Hodgkin lymphoma (HG-NHL). It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (low-grade non-Hodgkin lymphoma cancer only) reported quality of life measured using questionnaire QLQ-NHL-LG20, a validated 20-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with low-grade non-Hodgkin lymphoma (LG-NHL). It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (esophageal cancer only) reported quality of life measured using questionnaire QLQ-OES18 a validated 18-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with esophageal cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (esophago-gastric cancer only) reported quality of life measured using questionnaire QLQ-OG25, a validated 25-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with esophago-gastric cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (ovarian cancer only) reported quality of life measured using questionnaire QLQ-OV28, a validated 28-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with ovarian cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (prostate cancer only) reported quality of life measured using questionnaire QLQ-PR25, a validated 25-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with prostate cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (gastric cancer only) reported quality of life measured using questionnaire QLQ-STO22, a validated 22-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with gastric cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (testicular cancer only) reported quality of life measured using questionnaire QLQ-TC26, a validated 26-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with testicular cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (thyroid cancer only) reported quality of life measured using questionnaire QLQ-THY34, a validated 34-item health-related quality of life questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) for patients with thyroid cancer. It is used in conjunction with either the core EORTC QLQ-C30 or the core EORTC QLQ-SURV100 questionnaire, depending on disease status, to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (breast cancer only) reported quality of life measured using the QLQ-BR-SURV40, a provisional 40-item survivorship-specific health-related quality-of-life questionnaire in phase IV development by the European Organization for Research and Treatment of Cancer (EORTC) for disease-free breast cancer patients 1 year post-treatment. It is used in conjunction with the QLQ-BR42, a validated 42-item health-related quality of life questionnaire for breast cancer patients, and the core EORTC QLQ-SURV100 questionnaire to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (prostate cancer only) reported quality of life measured using the QLQ-PR-SURV19, a provisional 19-item survivorship-specific health-related quality-of-life questionnaire in phase IV development by the European Organization for Research and Treatment of Cancer (EORTC) for disease-free prostate cancer patients 1 year post-treatment. It is used in conjunction with the QLQ-PR25, a validated 25-item health-related quality of life questionnaire for prostate cancer patients, and the core EORTC QLQ-SURV100 questionnaire to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.

Patient (colorectal cancer only) reported quality of life measured using the QLQ-QLQ-CR-SURV33, a provisional 33-item survivorship-specific health-related quality-of-life questionnaire in phase IV development by the European Organization for Research and Treatment of Cancer (EORTC) for disease-free colorectal cancer patients 1 year post-treatment. It is used in conjunction with the QLQ-CR29, a validated 29-item health-related quality of life questionnaire for colorectal cancer patients, and the core EORTC QLQ-SURV100 questionnaire to assess health-related quality of life, including aspects of symptom burden, physical condition, fatigue, emotional impact, and worries about health, which allows for better evaluation of treatments. An estimate of the average of the items in the scale is the raw score. The raw score is linearly transformed to a 0-100-point range with higher scores indicating a higher ("better") level of functioning or a higher ("worse") level of symptoms.